Literature DB >> 11369661

Loss of red cell A, B, and H antigens is frequent in myeloid malignancies.

T Bianco1, B J Farmer, R E Sage, A Dobrovic.   

Abstract

Loss of A, B, and H antigens from the surface of red blood cells has been a recurrent observation in patients with hematologic malignancy, particularly those malignancies in which the myeloid lineage is involved. To better understand this phenomenon, a 2-color flow cytometric method was developed to determine quantitative and qualitative alterations of A, B, and H antigens in patients with myeloid malignancies. Characteristic patterns, dependent on the genotype, were seen for healthy individuals from each of the blood groups. Fifty-five percent (16/29) of patients of blood group A, B, or AB had a proportion of red cells with decreased expression of A or B antigens compared with no changes in 127 healthy A, B, and AB individuals. In most cases, the changes were not detected by routine serologic typing. The loss of A or B antigens was the primary change in 28% (8/29) of patients. In 17% (5/29) of patients, loss of A or B antigens was an indirect consequence of loss of the precursor H antigen. Alterations involving both the H and the A or B antigens were seen in 10% (3/29) of patients. Loss of H was also detected in 21% (6/28) of group O patients whereas none of 51 healthy O individuals showed changes. Alterations of ABO antigens can now be considered a common event in myeloid malignancy. (Blood. 2001;97:3633-3639)

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11369661     DOI: 10.1182/blood.v97.11.3633

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

1.  Blood Group Change in Pediatric Leukemia: A Rare Phenomena.

Authors:  Venkatraman Radhakrishnan; Sourav Mishra; Narmada Bhaskar; Tenali Sagar
Journal:  Indian J Pediatr       Date:  2016-01-25       Impact factor: 1.967

Review 2.  Simple sugars to complex disease--mucin-type O-glycans in cancer.

Authors:  Matthew R Kudelka; Tongzhong Ju; Jamie Heimburg-Molinaro; Richard D Cummings
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

3.  Low frequency of blood group A in primary central nervous system lymphoma.

Authors:  Manouchehr Gharouni; Mehdi Abouzari; Armin Rashidi; Nasim Sodagari; Mehrdad Behzadi
Journal:  J Neurooncol       Date:  2008-01-22       Impact factor: 4.130

4.  Sequence-Based Typing of Human Blood Groups.

Authors:  Axel Seltsam; Andrea Doescher
Journal:  Transfus Med Hemother       Date:  2009-05-14       Impact factor: 3.747

5.  Characterization and statistical modeling of glycosylation changes in sickle cell disease.

Authors:  Heather E Ashwood; Christopher Ashwood; Anna P Schmidt; Rebekah L Gundry; Karin M Hoffmeister; Waseem Q Anani
Journal:  Blood Adv       Date:  2021-03-09

Review 6.  Cancer intelligence acquired (CIA): tumor glycosylation and sialylation codes dismantling antitumor defense.

Authors:  Kayluz Frias Boligan; Circe Mesa; Luis Enrique Fernandez; Stephan von Gunten
Journal:  Cell Mol Life Sci       Date:  2014-12-07       Impact factor: 9.261

7.  Low frequency of blood group A in secondary central nervous system lymphoma.

Authors:  Mehdi Abouzari; Mehrdad Behzadi; Armin Rashidi
Journal:  Surg Neurol Int       Date:  2012-08-27

8.  DNA methylation of the ABO promoter underlies loss of ABO allelic expression in a significant proportion of leukemic patients.

Authors:  Tina Bianco-Miotto; Damian J Hussey; Tanya K Day; Denise S O'Keefe; Alexander Dobrovic
Journal:  PLoS One       Date:  2009-03-10       Impact factor: 3.240

9.  Transcriptional regulation of fucosyltransferase 1 gene expression in colon cancer cells.

Authors:  Fumiko Taniuchi; Koji Higai; Tomomi Tanaka; Yutaro Azuma; Kojiro Matsumoto
Journal:  ScientificWorldJournal       Date:  2013-03-03

10.  Diminished expression of B antigen mimicking B3 phenotype in a patient with AML-M3: a rare case report.

Authors:  Rajeswari Subramaniyan
Journal:  Rev Bras Hematol Hemoter       Date:  2016-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.